Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 08, 2017 16:08 ET
|
Dermira, Inc.
-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...
Dermira to Present at Needham 16th Annual Healthcare Conference
March 28, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting
March 21, 2017 07:30 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Highlight Data for Three Clinical Programs at Annual Maui Derm Meeting
March 17, 2017 08:30 ET
|
Dermira, Inc.
New data for the Axillary Sweating Daily Diary patient-reported outcome instrument from the glycopyrronium tosylate Phase 2 trial in primary axillary hyperhidrosis to be highlighted Additional data...
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 07, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual Meeting
March 04, 2017 09:00 ET
|
Dermira, Inc.; UCB
Late-breaking, investigational 16-week data presented from the CIMPASI-1 and CIMPASI-2 trials showing CIMZIA demonstrated statistically and clinically significant improvements for patients with...
Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
March 03, 2017 08:23 ET
|
Dermira, Inc.
ORLANDO, Fla., March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Cowen and Company 37th Annual Health Care Conference
March 02, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Prices $168.5 Million Public Offering of Common Stock
March 01, 2017 19:47 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Proposed Public Offering of Common Stock
February 28, 2017 17:13 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...